Translational Medical Research Center of Lung Cancer in Liaoning Province, Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, China.
Front Immunol. 2022 Sep 14;13:988849. doi: 10.3389/fimmu.2022.988849. eCollection 2022.
With the arrival of the era of tumor immunotherapy, Immune Checkpoint Inhibitors have benefited countless tumor patients. However, the emergence of Immune-Related Adverse Events, especially Immune Checkpoint Inhibitor-Mediated Colitis (IMC), has become an important obstacle to immunotherapy. Therefore, it is very important to clarify the mechanism and influencing factors of IMC. The effect of gut microbiota on IMC is gradually becoming a research hotspot. Gut microbiota from different phyla can affect IMC by regulating innate and acquired immunity of tumor patients in various ways. In this review, we make a systematic and comprehensive introduction of the effect of gut microbiota on IMC. Through understanding the specific effects of gut microbiota on IMC, and then exploring the possibility of reducing IMC by regulating gut microbiota.
随着肿瘤免疫治疗时代的到来,免疫检查点抑制剂使无数肿瘤患者受益。然而,免疫相关不良事件的出现,特别是免疫检查点抑制剂介导的结肠炎(IMC),已成为免疫治疗的重要障碍。因此,阐明 IMC 的机制和影响因素非常重要。肠道微生物群对 IMC 的影响逐渐成为研究热点。来自不同门的肠道微生物群可以通过调节肿瘤患者的先天和获得性免疫,以各种方式影响 IMC。在这篇综述中,我们对肠道微生物群对 IMC 的影响进行了系统和全面的介绍。通过了解肠道微生物群对 IMC 的具体影响,然后探索通过调节肠道微生物群来降低 IMC 的可能性。